Immunotherapy of urological tumours

著者

書誌事項

Immunotherapy of urological tumours

edited by J.B. deKernion ; foreword by Etienne Mazeman

Churchill Livingstone, 1989

大学図書館所蔵 件 / 全8件

この図書・雑誌をさがす

注記

Proceedings of the 21st Congress of the Société internationale d'urologie held Oct. 1988 in Buenos Aires

内容説明・目次

内容説明

This monograph contains the majority of the proceedings of the triennial meeting of the Societe Internationale d'Urologie, held in Buenos Aires in October 1988. It looks at the information available on the evaluation of the results of immunological treatment of urological tumours. The contributors are drawn from all over the world and topics include intravesical instillation therapy using interferon for the treatment of bladder cancer.

目次

  • Part 1 Intravesical therapy with Bacillus Calmette-Guerin: Bacillus Calmette-Guerin immunotherapy in bladder cancer, N.Netto Jr and C.D'Ancona
  • immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer, K.Jauhiainen et al
  • prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer
  • mitomycin C vs BCG Connaught v Tur alone, H.Rubben et al
  • five-year follow-up of bladder tumours treated with BCG, O.Gogus et al
  • prevention of recurrence of superficial bladder cancer with BCG, S.Vildosola et al
  • the significance of tumour histology in the results of treatment with intravesical BCG for superficial bladder cancer, H.Winkler et al
  • intravesical BCG for superficial bladder cancer - comparison of results on primary tumour to development of progressive disease elsewhere, J.D.Schmidt
  • BCG vs doxorubicin v thiotepa instillation for primary superficial bladder cancer, interim report of a randomized prospective study, J.A.Martinez-Pineiro et al
  • low-dose BCG therapy in superficial bladder cancer - a clinicopathological prospective study, F.Pagano et al
  • effects of local BCG therapy in patients with bladder carcinoma on phenotypes and function of mononuclear cells, A.Bohle et al
  • intravesical BCG therapy in patients with superficial bladder cancer, A.Steg et al
  • analysis and commentary - intravesical therapy with BCG, J.B.de Kernion. Part 2 Other intravesical agents: intravesical alpha-interferon in the treatment of superficial bladder cancer, R.D.Williams
  • intravesical instillation therapy using interferon for treatment of bladder cancer, M.Hara et al
  • immunotherapy with keyhole-limpet haemocyanin (KLH) as prophylaxis against superficial bladder tumour recurrence, C.Jurincic et al
  • pilot study on the effects of peritumoral and intranodal injection of low doses of interferon-gamma in patients with recurrent superficial bladder carcinoma, G.Fontana et al
  • the prevention of recurrence of superficial bladder tumours with immunochemotherapy, K.Matsumoto et al
  • analysis and commentary - other intravesical agents, J.B.de Kernion. Part 3 Immunotherapy of renal cell carcinoma: combination therapy with recombinant interferon-alpha and -gamma in advanced renal cell carcinoma-a phase 1-11 study, M.P.H.Franssen et al
  • biologic response modifier therapy of metastatic renal cell carcinoma - the UCLA experience, R.Figlin et al
  • human lymphoblastoid interferon treatment of metastatic renal cell carcinoma, T.Kawai et al
  • long-term interferon treatment in metastatic renal cell carcinoma, W.Levens et al
  • adjunctive interferon treatment in non-metastatic renal cell carcinoma, W.Levens et al. (Part contents)

「Nielsen BookData」 より

詳細情報

ページトップへ